Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP843608.RAZVGn6lOR__XnILxX7UVwAPov6RoiK94ATsG-yx3doOc130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP843608.RAZVGn6lOR__XnILxX7UVwAPov6RoiK94ATsG-yx3doOc130_provenance.
• NP220794.RAxZ2TkAIZcBwUj-_crMrad770lu6FpMHjVpxg2uG-a-Y130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP220794.RAxZ2TkAIZcBwUj-_crMrad770lu6FpMHjVpxg2uG-a-Y130_provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP225015.RAUTl3Tz19QyCuvMaHibAcj_Ap58hkbtWFbI79pnifIto130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225015.RAUTl3Tz19QyCuvMaHibAcj_Ap58hkbtWFbI79pnifIto130_provenance.
• NP858998.RAd41ruWYPs0-PQzLnPsRYk-fKMkioz4p-hJ5i68dw3Mo130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP858998.RAd41ruWYPs0-PQzLnPsRYk-fKMkioz4p-hJ5i68dw3Mo130_provenance.
• NP803853.RAYh3EdJQFFcbbi_02JxxaRhhg0TfC4LCLvtPj5Pljhsw130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803853.RAYh3EdJQFFcbbi_02JxxaRhhg0TfC4LCLvtPj5Pljhsw130_provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP998866.RATgSUh9_FvQRmFaM2HfNBOoJnfSJILhmQWoe_6bRgjpY130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998866.RATgSUh9_FvQRmFaM2HfNBOoJnfSJILhmQWoe_6bRgjpY130_provenance.
• NP998873.RAQBBZUzdrLdpEaDvEw_t5sWOJ23A1dIvuLi7qICzvr1k130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998873.RAQBBZUzdrLdpEaDvEw_t5sWOJ23A1dIvuLi7qICzvr1k130_provenance.
• NP998874.RAeR7BUpBBcqbDuREZAzBSNKww3s4OxwhvJ2DfbvnryFM130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998874.RAeR7BUpBBcqbDuREZAzBSNKww3s4OxwhvJ2DfbvnryFM130_provenance.
• NP998875.RAc3OHWwesJO3SIhIKc6JTs3b3MmYDPcP8cvBDVC2Clfw130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998875.RAc3OHWwesJO3SIhIKc6JTs3b3MmYDPcP8cvBDVC2Clfw130_provenance.
• NP998876.RAQOThRYPhJGEucAe6dv_p9bZC4yWWuuUJulfKqM2gYOA130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998876.RAQOThRYPhJGEucAe6dv_p9bZC4yWWuuUJulfKqM2gYOA130_provenance.
• NP998877.RATDVMGq_havJpUSzwdJ1AGioNDc_j7bcu_rOUmHwN4Mk130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998877.RATDVMGq_havJpUSzwdJ1AGioNDc_j7bcu_rOUmHwN4Mk130_provenance.
• NP225014.RAjlHsRKoWmQxn2GfqDv7PLS9YvHo_QJ42M1LRqdazvys130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225014.RAjlHsRKoWmQxn2GfqDv7PLS9YvHo_QJ42M1LRqdazvys130_provenance.
• NP803309.RAshLPn6ROAIXIdgpk2cZ_pwx3qW5kiZpiwVJRllDpomY130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803309.RAshLPn6ROAIXIdgpk2cZ_pwx3qW5kiZpiwVJRllDpomY130_provenance.
• NP803851.RAvu4N3OvilRm-BMepcibVQuD2FtCwsjw-b6giM_aeXSs130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803851.RAvu4N3OvilRm-BMepcibVQuD2FtCwsjw-b6giM_aeXSs130_provenance.
• NP880626.RAu54qt6c28pFZ5ONBJkMsvUyHghfsWj_rBnKU1vNOXdo130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP880626.RAu54qt6c28pFZ5ONBJkMsvUyHghfsWj_rBnKU1vNOXdo130_provenance.
• NP998867.RAPIx8yfVoGe85cMcV9lSo5tGVevqKX1xoa4Ek_eTguv4130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998867.RAPIx8yfVoGe85cMcV9lSo5tGVevqKX1xoa4Ek_eTguv4130_provenance.
• NP998870.RANL6uaKNgmM29LXmjZ82tZcouQmwtIRVehi7UgMPnabE130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998870.RANL6uaKNgmM29LXmjZ82tZcouQmwtIRVehi7UgMPnabE130_provenance.
• NP998872.RAIfYUmWp9rwQj1nkQv04-2Rv6iRO_hpJo9Z6HVmcbfrE130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998872.RAIfYUmWp9rwQj1nkQv04-2Rv6iRO_hpJo9Z6HVmcbfrE130_provenance.
• NP998878.RAM8HG9v8pkMp3AhENxLbZrwNQefaBcdV0TrqO-K_EiGw130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998878.RAM8HG9v8pkMp3AhENxLbZrwNQefaBcdV0TrqO-K_EiGw130_provenance.
• NP880627.RAKiguIRX6z_X2Ie0Wsy1A4Q_fyiRNG89tlvU79Fv3eOM130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP880627.RAKiguIRX6z_X2Ie0Wsy1A4Q_fyiRNG89tlvU79Fv3eOM130_provenance.
• NP803310.RAwOzPgkVVK0OLZ7KMQ8XuGh7v59uCthschVXrZdcpAAY130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803310.RAwOzPgkVVK0OLZ7KMQ8XuGh7v59uCthschVXrZdcpAAY130_provenance.
• NP858997.RA_GlXFvYIXr-o450hFVe3fgouPH-NE1IeifyT3zx_ksc130_assertion description "[These data provide new insights into TRAIL-induced necroptosis with PARP-1 being active effector downstream of RIPK1/RIPK3 initiators and suggest that pharmacological inhibitors of RIPKs and PARP-1 could be new treatment options for immune-mediated hepatitis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP858997.RA_GlXFvYIXr-o450hFVe3fgouPH-NE1IeifyT3zx_ksc130_provenance.